Conference on Retroviruses and Opportunistic Infections (CROI)

Conference on Retroviruses and Opportunistic Infections (CROI)

February 24, 2015
1 min read

Patients with HIV/HCV may require ART switch to receive Olysio

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

In a cohort of patients coinfected with HIV and hepatitis C virus, a majority were required to undergo an antiretroviral therapy switch before beginning treatment with Olysio, according to data from a poster presentation at CROI 2015.

“These findings are significant to real-world clinical practice settings and highlight the complexity of using interferon-free [direct-acting antivirals] in this population and add further stress to an already burdened HIV care delivery system,” the researchers wrote.

Researchers from the University of Pittsburgh and University of Maryland conducted a retrospective chart review at the University of Pittsburgh Medical Center’s HIV/AIDS Program between June and October 2014 using data from 133 patients coinfected with HIV/HCV. Of these patients, 71% were male, 86% had HCV genotype 1 and 94% were undergoing ART.

Overall, 38% of patients were assigned a ritonavir-boosted regimen, 34% Sustiva (efavirenz, Bristol-Myers Squibb), 11% Isentress (raltegravir, Merck), 6% Edurant (rilpivirine, Janssen), 4% Tivicay (dolutegravir, ViiV Healthcare) and 1% elvitegravir/cobicistat (Gilead Sciences), according to the abstract.   

Seventy-seven percent of patients (103/133) required an ART switch before being treated with Olysio (simeprevir, Janssen Therapeutics). Of these patients, a straightforward substitution was an option in 47 patients, another 40 patients were considered for a switch only after opinion from an HIV expert, and a switch was impossible for 16 patients as a result of HIV drug resistance mutations.  

More than 30% of patients on a protease inhibitor could not undergo an ART switch.

“The majority of HIV/HCV coinfected patients will require ART switch prior to use of [simeprevir],” the researchers concluded. “Additionally, for nearly a third of patients on a [protease inhibitor], an ART switch may not be feasible.”


Cope R, et al. Poster 651. Presented at: Conference on Retroviruses and Opportunistic Infections; Feb. 23-26, 2015; Seattle.

Disclosure: Relevant financial disclosures were unavailable.